Showing results (2631-2640 of 2,696) with videos related to

Sort By:
Pageof 270
The Lancet. Infectious Diseases|October 9, 2025
Characterising household transmission dynamics of clade Ib mpox in Burundi: a prospective cohort studyRaoul Kamadjeu, Ferdinand Nsengimana, Manassé Nimpagaritse, et al.
The Lancet. Infectious Diseases|October 10, 2025
Core outcome measurement set for clinical trials in dengue: an international Delphi consensus study (DEN-CORE)Sophie Yacoub, Anastasia Demidova, Xin Hui S Chan, et al.
The Lancet. Infectious Diseases|October 3, 2025
Long COVID associated with SARS-CoV-2 reinfection among children and adolescents in the omicron era (RECOVER-EHR): a retrospective cohort studyBingyu Zhang, Qiong Wu, Ravi Jhaveri, et al.
The Lancet. Infectious Diseases|October 2, 2025
Management of individuals exposed to multidrug-resistant or rifampicin-resistant tuberculosisJames A Seddon, Jay Achar, Amyn A Malik, et al.
The Lancet. Infectious Diseases|September 13, 2025
Rifasutenizol-based triple therapy versus bismuth plus clarithromycin-based triple therapy for first-line treatment of Helicobacter pylori infection in China (EVEREST-HP): a phase 3, multicentre, randomised, triple-dummy, double-blind, controlled, non-inferiority trialZhiqiang Song, Liya Zhou, Weihong Wang, et al.
The Lancet. Infectious Diseases|September 7, 2025
A 3-month clofazimine-rifapentine-containing regimen for drug-susceptible tuberculosis versus standard of care (Clo-Fast): a randomised, open-label, phase 2c clinical trialJohn Z Metcalfe, Isabelle R Weir, Kimberly K Scarsi, et al.
The Lancet. Infectious Diseases|September 11, 2025
Autoantibodies in long COVID: a systematic reviewFabian Wilhelm, Janne Cadamuro, Sylvia Mink
The Lancet. Infectious Diseases|August 1, 2025
Effectiveness of the BNT162b2 and mRNA-1273 JN.1-adapted vaccines against COVID-19-associated hospitalisation and death: a Danish, nationwide, register-based, cohort studyChristian Holm Hansen, Ria Lassaunière, Morten Rasmussen, et al.
The Lancet. Infectious Diseases|June 28, 2025
Efficacy and safety of ascending doses of emodepside in comparison with ivermectin in adults infected with Strongyloides stercoralis in Laos: a phase 2a, dose-ranging, randomised, parallel-group, placebo-controlled, single-blind clinical trialLyndsay Taylor, Sysouphanh Many, Hannah Jeanguenat, et al.
The Lancet. Infectious Diseases|June 20, 2025
Olorofim for the treatment of invasive fungal diseases in patients with few or no therapeutic options: a single-arm, open-label, phase 2b studyJohan A Maertens, George R Thompson, Andrej Spec, et al.
Pageof 270